ClinicalTrials.gg
CompletedNCT00950859Updated Dec 4, 2015Results posted

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

A Phase 2 interventional study of GSK1349572 (Cohort I) and GSK1349572 (Cohort II) in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-04.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus from multiplying.

GSK1349572 has shown to be effective against viruses in a short-term monotherapy study in adults with no previous exposure to integrase inhibitors. The purpose of this study is to determine whether GSK1349572 is effective in the treatment of HIV-infected patients who no longer respond to treatment with the approved integrase inhibitor raltegravir and carry viruses with resistance to this drug. The safety and efficacy of GSK1349572 50mg once daily in combination with the background HIV drugs previously administered (unless discontinuation of a particular drug is required) will be assessed over 10 days (functional monotherapy phase), followed by the evaluation of the safety and efficacy of GSK1349572 given with a new optimised background regimen from Day 11 through at least Week 24.

Read the detailed description

Study (ING112961) is a Phase IIb, multicentre, open-label, single arm, two cohorts, pilot study to assess the antiviral activity of GSK1349572 containing regimen in HIV-1 infected ART-experienced adults with raltegravir (RAL) resistance. The study will include approximately 50 ART-experienced subjects with either current or past virologic failure to RAL. All subjects must harbour isolates with RAL resistance mutations at Screening. Subjects should also have documented genotypic and/or phenotypic resistance to at least one compound from each of three or more of the approved classes of ART (including integrase inhibitors [INIs]). Subjects with current RAL virologic failure will substitute RAL with GSK1349572 50mg once daily and continue the remaining components of their failing regimen through Day 10. Subjects with historical RAL virologic failure will add GSK1349572 50mg once daily to their failing regimen through Day 10. On Day 11 all subjects will continue GSK1349572 and optimize their background therapy. Antiviral activity, safety and tolerability of GSK1349572 will be evaluated at Day 11 and over time through at least Week 24.

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • treatment experienced
  • HIV Infection
  • raltegravir resistance
  • GSK1349572
  • optimized background regimen
  • integrase inhibitor
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 51 is below the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infected male or female adults at least 18 years of age with a plasma HIV-1 RNA > 1,000 copies/mL at study entry. Women capable of becoming pregnant must use appropriate during the study (as defined by the protocol)
  • ART-experienced (defined as on stable ART for at least the last 2 months) and is either currently experiencing virologic failure to RAL or experienced virologic failure to RAL > 8 weeks prior to Screening
  • Must have documented RAL genotypic resistance on study entry genotype
  • Must have documented genotypic or phenotypic resistance to at least one drug from each of three or more of all approved classes of ART
  • For Cohort II, Subjects MUST be able to receive at least one fully active drug as part of the Day 11 optimised background regimen
  • Willing and able to understand and provide signed and dated written prior to screening

Exclusion criteria

Exclusion Criteria:

  • Any pre-existing mental, physical, or substance abuse disorder which, which could compromise ability to comply with the protocol or compromise subject safety
  • Women who are pregnant or breastfeeding
  • An active AIDS-defining condition at the screening visit
  • Currently take and/or anticipated need for EFV, NVP, FPV/RTV or TPV/RTV during the study
  • Treatment with any of the following medications within 15 days of starting study drug, or anticipated to need, during the course of the study: Etravirine (unless co-administered with LPV/RTV or DRV/RTV), rifampin, rifabutin, phenytoin, phenobarbital, barbiturates, , modafinil, oxcarbazepine, pioglitazone, troglitazone, carbamazepine, St. Johns wort
  • Previous participation in an experimental drug and/or vaccine trial(s) within 30 days or 5 half-lives
  • History of ongoing or pancreatitis or hepatitis within the previous 6 months
  • Expected to require treatment for infection during the first 24 weeks of the study
  • Evidence of cirrhosis with or without hepatitis viral co-infection
  • History of upper gastrointestinal bleed and/or active peptic ulcer disease
  • Screening \<10g/dL (100g/L)
  • Subject suffers from a serious medical condition which could compromise the safety of the subject.
  • Any condition that could interfere with the absorption, distribution, metabolism or excretion of the drug or render the subject unable to take oral medication
  • Screening lipase 3 times the (ULN)
  • Any acute or Grade 4 laboratory abnormality at screening
  • Screening (ALT) >5xULN
  • Screening ALT 3xULN and 1.5xULN (with 35% direct bilirubin)
  • Personal or family history of prolonged syndrome.
  • Any clinically significant finding, as specified in the protocol, on screening or baseline electrocardiograph ()
  • History of allergy to the study drugs or their components or drugs of their class
  • Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to screening, or future need of treatment with these agents during the study
  • Treatment with immunomodulators within 28 days prior to screening or subject has received an -1 vaccine within 90 days prior to screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    GSK1349572 Cohort I

    Single Arm, Cohort I

    Drug: GSK1349572 (Cohort I)

  • Experimental
    GSK1349572 Cohort II

    Single Arm, Cohort II

    Drug: GSK1349572 (Cohort II)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11

    The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.

    Time frame: Baseline (Day 1) and Day 11

Secondary outcomes

  1. Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion

    Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Day 6 to 8; Day 11; Weeks 4, 12, 24, 48, 72, 96, from 108 every 12 weeks up to study completion

  2. Number of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.

    The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

    Time frame: Baseline; Weeks 4, 12, 24, 48, 72, and 96

  3. Proportion of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL From Week 48 Every 12 Weeks up to Study Completion

    The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: From Week 48 every 12 weeks up to study completion

  4. Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion

    Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Day 11; Weeks 4, 12, 24, 48, 72, 96, from Week 108 every 12 weeks up to study completion

  5. Cmax, Cmin, and Ctau of DTG

    The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

    Time frame: Day 10

  6. C0 Assessment of DTG

    The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).

    Time frame: Day 10; Weeks 4 and 24

  7. Tmax of DTG

    The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

    Time frame: Day 10

  8. AUC0-24 Assessment of DTG

    AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

    Time frame: Day 10

  9. Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences

    The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

    Time frame: From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)

  10. Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death

    The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

    Time frame: From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)

  11. Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion

    PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.

    Time frame: Day 11; Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, from Week 108 every 12 weeks up to study completion

  12. Number of Participants With the Indicated Genotypic Resistance at Baseline

    At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.

    Time frame: Baseline

  13. Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group

    Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.

    Time frame: Baseline (Day 1)

  14. Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance

    An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.

    Time frame: From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)

  15. Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance

    The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log 10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log 10 c/mL unless \<400 c/mL or an increase of \>=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.

    Time frame: From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)

  16. Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities

    Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.

    Time frame: From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II

  17. Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities

    Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.

    Time frame: From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II

07

Results

Posted Oct 21, 2013

Participant flow

Participants recruited initially to Cohort I and subsequently to Cohort II. Recruitment to Cohort I was closed 9 months before recruitment to Cohort II was opened. Recruitment was not randomized.

Participant flow — Overall Study
MilestoneCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Started2724
Completed1114
Not completed1610
Withdrew: Adverse event33
Withdrew: Insufficient viral load response123
Withdrew: Protocol violation11
Withdrew: Lost to follow-up03

Outcome measures

PrimaryNumber of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11

The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.

Time frame:
Baseline (Day 1) and Day 11
Reported as:
Number · Participants
Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 112123
Statistical analysis
  • Cohort I (DTG 50 mg OD) · Percentage of participants: 78 · 95% CI 58 to 91The estimated value represents the percentage of participants with HIV-1 RNA \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11.
  • Cohort II (DTG 50 mg BID) · Percentage of participants: 96 · 95% CI 79 to 100The estimated value represents the percentage of participants with HIV-1 RNA \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11.
SecondaryMean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion

Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Day 6 to 8; Day 11; Weeks 4, 12, 24, 48, 72, 96, from 108 every 12 weeks up to study completion
Reported as:
Mean · Log10 copies/mL
Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion
Log10 copies/mLCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Day 6 to 8, n=27, 24-1.31 ± 0.71-1.40 ± 0.43
Day 11, n=27, 24-1.45 ± 0.77-1.76 ± 0.53
Week 4, n=26, 24-1.82 ± 1.03-2.06 ± 0.78
Week 12, n=22, 24-1.94 ± 1.14-2.30 ± 0.93
Week 24, n=18, 22-1.99 ± 1.08-2.50 ± 0.81
Week 48, n=15, 20-2.02 ± 1.07-2.63 ± 0.78
Week 72, n=14, 18-2.10 ± 1.03-2.71 ± 0.82
Week 96, n=13, 15-2.06 ± 1.13-2.58 ± 0.77
Week 108, n= 13, 17-1.95 ± 1.20-2.69 ± 0.82
Week 120, n= 11, 17-2.09 ± 1.15-2.67 ± 0.85
Week 132, n= 11, 17-1.83 ± 1.01-2.66 ± 0.86
Week 144, n= 12, 15-2.08 ± 1.29-2.62 ± 0.94
Week 156, n= 12, 15-2.04 ± 1.36-2.65 ± 0.77
Week 168, n= 11, 14-1.77 ± 1.26-2.72 ± 0.89
Week 180, n= 11, 10-1.76 ± 1.11-2.56 ± 0.82
Week 192, n= 9, 7-1.87 ± 1.16-2.51 ± 0.98
Week 204, n= 10, 6-1.76 ± 1.21-2.35 ± 0.71
Week 216, n= 9, 6-1.61 ± 1.08-2.35 ± 0.71
Week 228, n= 6, 4-1.79 ± 1.08-2.33 ± 0.90
Week 240, n= 7, 0-1.63 ± 1.13NA ± NA
Week 252, n= 4, 0-1.72 ± 1.07NA ± NA
Week 264, n= 1, 0-2.90 ± NANA ± NA
SecondaryNumber of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.

The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.

Time frame:
Baseline; Weeks 4, 12, 24, 48, 72, and 96
Reported as:
Number · Participants
Number of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Baseline, <50 c/mL00
Week 4, <50 c/mL912
Week 12, <50 c/mL1316
Week 24, <50 c/mL1119
Week 48, <50 c/mL917
Week 72, <50 c/mL8NA
Week 96, <50 c/mL7NA
Baseline, <400 c/mL00
Week 4, <400 c/mL1617
Week 12, <400 c/mL1620
Week 24, <400 c/mL1420
Week 48, <400 c/mL1318
Week 72, <400 c/mL12NA
Week 96, <400 c/mL10NA
SecondaryProportion of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL From Week 48 Every 12 Weeks up to Study Completion

The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
From Week 48 every 12 weeks up to study completion
Reported as:
Number · Percentage of Participants
Proportion of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL From Week 48 Every 12 Weeks up to Study Completion
Percentage of ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Week 48, <50 c/mL, n=15, 206080
Week 60, <50 c/mL, n=13, 186994
Week 72, <50 c/mL, n=14, 186478
Week 84, <50 c/mL, n=14, 185778
Week 96, <50 c/mL, n=13, 155487
Week 108, <50 c/mL, n=13, 175488
Week 120, <50 c/mL, n=11, 175588
Week 132, <50 c/mL, n=11, 175582
Week 144, <50 c/mL, n=12, 155887
Week 156, <50 c/mL, n=12, 156793
Week 168, <50 c/mL, n=11, 146486
Week 180, <50 c/mL, n=11, 1064100
Week 192, <50 c/mL, n= 9, 767100
Week 204, <50 c/mL, n= 10, 650100
Week 216, <50 c/mL, n= 9, 656100
Week 228, <50 c/mL, n=6, 467100
Week 240, <50 c/mL, n=7,057NA
Week 252, <50 c/mL, n=4, 050NA
Week 264, <50 c/mL, n=1, 0100NA
Week 48, <400 c/mL, n=15, 207395
Week 60,<400 c/mL, n=13, 1892100
Week 72,<400 c/mL, n=14, 1879100
Week 84,<400 c/mL, n=14, 187194
Week 96,<400 c/mL, n=13, 1585100
Week 108,<400 c/mL, n=13,1785100
Week 120,<400 c/mL, n=11, 178294
Week 132,<400 c/mL, n=11,178294
Week 144,<400 c/mL, n=12, 158393
Week 156,<400 c/mL, n=12, 1575100
Week 168,<400 c/mL, n=11, 1482100
Week 180,<400 c/mL, n=11, 1073100
Week 192,<400 c/mL, n=9, 778100
Week 204,<400 c/mL, n=10, 670100
Week 216,<400 c/mL, n=9, 656100
Week 228,<400 c/mL, n=6, 467100
Week 240,<400 c/mL, n=7, 071NA
Week 252,<400 c/mL, n=4, 050NA
Week 264,<400 c/mL, n=1, 0100NA
SecondaryChange From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion

Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Day 11; Weeks 4, 12, 24, 48, 72, 96, from Week 108 every 12 weeks up to study completion
Reported as:
Median · cells per cubic millimeter (mm^3)
Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion
cells per cubic millimeter (mm^3)Cohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Baseline, n=27, 24114 (44 to 227)202 (19 to 384)
Day 11, n=27, 2434 (2 to 71)14 (0 to 69)
Week 4, n=27, 2457 (33 to 108)35 (8 to 69)
Week 12, n= 22, 2484 (26 to 124)57 (8 to 103)
Week 24, n=17, 2278 (54 to 175)79 (17 to 147)
Week 48, n=15, 20102 (29 to 160)106 (45 to 245)
Week 72, n=14, 18163 (58 to 204)191.5 (80 to 277)
Week 96, n=13, 15142 (75 to 202)189 (75 to 280)
Week 108, n=13, 17124 (68 to 249)155 (91 to 276)
Week 120, n=11, 17221 (62 to 306)221 (135 to 314)
Week 132, n=11, 1797 (26 to 303)158 (129 to 384)
Week 144, n=12, 15121 (28 to 284)278 (113 to 340)
Week 156, n=12, 15212 (64 to 378)223 (131 to 309)
Week 168, n=11, 1397 (-102 to 365)271 (93 to 357)
Week 180, n=11, 10125 (55 to 327)224 (163 to 288)
Week 192, n=10, 794 (61 to 291)343 (304 to 429)
Week 204, n=10, 692 (47 to 364)264 (186 to 370)
Week 216, n=9, 6172 (48 to 416)252 (147 to 421)
Week 228, n=7, 3148 (66 to 357)417 (-12 to 633)
Week 240, n=7, 0158 (119 to 470)NA (NA to NA)
Week 252, n=4, 0157 (109 to 282)NA (NA to NA)
Week 264, n=1, 0560 (560 to 560)NA (NA to NA)
SecondaryCmax, Cmin, and Ctau of DTG

The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

Time frame:
Day 10
Reported as:
Geometric mean · Micrograms per milliliter (µg/mL)
Cmax, Cmin, and Ctau of DTG
Micrograms per milliliter (µg/mL)Cohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Cmax3.04 ± 385.41 ± 40
Ctau0.69 ± 912.72 ± 70
Cmin0.48 ± 1362.61 ± 67
SecondaryC0 Assessment of DTG

The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).

Time frame:
Day 10; Weeks 4 and 24
Reported as:
Geometric mean · µg/mL
C0 Assessment of DTG
µg/mLCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
C0, Day 100.51 ± 1393.20 ± 69
C0, Week 40.57 ± 1002.55 ± 63
C0, Week 240.38 ± 1142.38 ± 69
SecondaryTmax of DTG

The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

Time frame:
Day 10
Reported as:
Median · Hours
Tmax of DTG
HoursCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Tmax of DTG2.97 (1.97 to 7.92)2.00 (0.00 to 7.87)
SecondaryAUC0-24 Assessment of DTG

AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.

Time frame:
Day 10
Reported as:
Geometric mean · Micrograms*hour per milliliter (µg*hr/mL
AUC0-24 Assessment of DTG
Micrograms*hour per milliliter (µg*hr/mLCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
AUC0-24 Assessment of DTG36.46 ± 5393.36 ± 50
SecondaryNumber of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences

The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

Time frame:
From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Reported as:
Number · Participants
Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Category B, Candidiasis, oropharyngeal32
Category B, Hairy leukoplakia, oral20
Category B, Herpes Zoster20
Category C, Herpes simplex10
Category C, Candidiasis, esophageal01
Category C, Cytomegalovirus retinitis01
Category C, Kaposi's sarcoma10
Category C, Lymphoma, Burkitt's01
Category C, Lymphoma, immunoblastic10
Death, Brain mass10
Death, Completed suicide01
Death, Febrile bone marrow aplasia10
Death, Immunoblastic lymphoma10
Death, Acute pulmonary oedema10
Death, Anaemia01
Death, Haemochromatosis01
Death, Hepatic fibrosis01
Other: Cryptosporidiosis, acute intestinal01
Other: leukoplasia of both side of the tongue10
SecondaryNumber of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death

The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).

Time frame:
From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Reported as:
Number · Participants
Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
From CDC class A to CDC class C02
From CDC class B to CDC class C02
From CDC class C to new CDC class C10
From CDC Class A, B, or C to death32
SecondaryNumber of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion

PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.

Time frame:
Day 11; Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, from Week 108 every 12 weeks up to study completion
Reported as:
Number · Participants
Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Day 1161
Week 873
Week 1293
Week 16105
Week 20105
Week 24125
Week 32125
Week 40125
Week 48135
Week 60135
Week 72146
Week 84156
Week 96166
Week 108166
Week 120166
Week 132166
Week 144167
Week 156167
Week 168167
Week 180167
Week 192167
Week 204167
Week 216177
Week 228187
Week 24018NA
Week 25218NA
Week 26418NA
SecondaryNumber of Participants With the Indicated Genotypic Resistance at Baseline

At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With the Indicated Genotypic Resistance at Baseline
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Q148 + 232
Q 148 + 148
Mixture21
Y143126
N15546
Other21
SecondaryMedian Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group

Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.

Time frame:
Baseline (Day 1)
Reported as:
Median · Percentage
Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group
PercentageCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Q148 + 2, n=3, 221 (14 to 35)4 (2.1 to 6.0)
Q148 + 1, n=4, 85.5 (3.3 to 25)5.5 (4.1 to 8.2)
Mixture, n=2, 17.8 (6.5 to 9.1)9.48 (9.48 to 9.48)
Y143, n=12, 61.1 (0.6 to 1.4)1.2 (0.92 to 1.8)
N155, n=4, 61.8 (1.5 to 5.1)2.3 (1.3 to 4.0)
Other, n=2, 11.2 (0.9 to 1.5)0.87 (0.87 to 0.87)
SecondaryNumber of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance

An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.

Time frame:
From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Reported as:
Number · Participants
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Any115
E138T01
N155H34
T97A20
E92E/Q01
G140S30
L74I/M10
Q148H20
E138E/A10
E138E/K12
L74I/M/I10
L74M10
L74I10
T97T/A02
Q148R10
S147G30
E92E/V01
L68L/I10
SecondaryNumber of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance

The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log 10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log 10 c/mL unless \<400 c/mL or an increase of \>=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.

Time frame:
From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Reported as:
Number · Participants
Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
<1 fold30
1-<2 fold42
2-<4 fold10
4-<8 fold12
>=8 fold83
SecondaryNumber of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities

Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.

Time frame:
From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II
Reported as:
Number · Participants
Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Albumin, Grade 300
Albumin, Grade 400
Alkaline Phosphatase, Grade 300
Alkaline Phosphatase, Grade 400
Amylase, Grade 312
Amylase, Grade 410
Aspartate Amino Transferase, Grade 300
Aspartate Amino Transferase, Grade 400
Carbon dioxide content/Bicarbonate, Grade 300
Carbon dioxide content/Bicarbonate, Grade 400
Creatinine, Grade 300
Creatinine, Grade 400
Creatinine Clearance, estimated, Grade 300
Creatinine Clearance, estimated, Grade 400
Hypercalcemia, Grade 300
Hypercalcemia, Grade 400
Hyperglycaemia, Grade 300
Hyperglycaemia, Grade 400
Hyperkalemia, Grade 300
Hyperkalemia, Grade 400
Hypernatremia, Grade 310
Hypernatremia, Grade 400
Hypocalcemia, Grade 300
Hypocalcemia, Grade 400
Hypoglycaemia, Grade 310
Hypoglycaemia, Grade 401
Hypokalemia, Grade 300
Hypokalemia, Grade 400
Hyponatremia, Grade 300
Hyponatremia, Grade 400
LDL Cholesterol, Grade 321
LDL Cholesterol, Grade 400
Magnesium, Grade 300
Magnesium, Grade 400
Phosphorus inorganic, Grade 343
Phosphorus inorganic, Grade 400
Total Bilirubin, Grade 302
Total Bilirubin, Grade 401
Alanine Amino Transferase ,Grade 301
Alanine Amino Transferase ,Grade 400
Calcium,Grade 300
Calcium,Grade 400
Chloride,Grade 300
Chloride,Grade 400
Cholesterol,Grade 311
Cholesterol,Grade 400
Creatine Kinase,Grade 300
Creatine Kinase,Grade 400
Direct Bilirubin,Grade 300
Direct Bilirubin,Grade 400
Glucose,Grade 310
Glucose,Grade 401
HDL Cholesterol direct,Grade 300
HDL Cholesterol direct,Grade 400
Lipase,Grade 323
Lipase,Grade 411
Potassium,Grade 300
Potassium,Grade 400
Sodium,Grade 310
Sodium,Grade 400
Total Cholesterol/HDLratio, Grade 300
Total Cholesterol/HDLratio, Grade 400
Triglycerides,Grade 302
Triglycerides,Grade 400
Urea/BUN,Grade 300
Urea/BUN,Grade 400
SecondaryNumber of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities

Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.

Time frame:
From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II
Reported as:
Number · Participants
Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities
ParticipantsCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Hemoglobin, Grade 301
Hemoglobin, Grade 400
Platelet count, Grade 300
Platelet count, Grade 400
Total Neutrophils, Grade 300
Total Neutrophils, Grade 402
White Blood Cell count, Grade 300
White Blood Cell, Grade 401

Adverse events

Collected over SAEs, non-serious AEs and laboratory toxicities were collected from start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I (DTG 50 mg OD)—10/27 (37%)25/27 (92.6%)
Cohort II (DTG 50 mg BID)—11/24 (45.8%)22/24 (91.7%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
Coronary artery diseaseCardiac disorders0/272/24
Gastroenteritis viralInfections and infestations0/271/24
PneumoniaInfections and infestations0/271/24
Respiratory tract infectionInfections and infestations0/271/24
Staphylococcal abscessInfections and infestations0/271/24
AnaemiaBlood and lymphatic system disorders0/271/24
Febrile neutropeniaBlood and lymphatic system disorders0/271/24
Chest discomfortGeneral disorders0/271/24
Diabetes mellitusMetabolism and nutrition disorders0/271/24
HaemochromatosisMetabolism and nutrition disorders0/271/24
Most frequent other events
Showing 10 of 67
Most frequent other events
EventCohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)
DiarrhoeaGastrointestinal disorders8/279/24
BronchitisInfections and infestations6/277/24
PyrexiaGeneral disorders3/277/24
CoughRespiratory, thoracic and mediastinal disorders5/277/24
AstheniaGeneral disorders6/273/24
Upper respiratory tract infectionInfections and infestations2/275/24
InsomniaPsychiatric disorders5/272/24
ArthralgiaMusculoskeletal and connective tissue disorders5/272/24
FatigueGeneral disorders0/274/24
LymphadenopathyBlood and lymphatic system disorders2/274/24

Baseline characteristics

Age, Customized
Age, Customized(Years)Cohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)Total
Years48 (19 to 61)47 (33 to 68)47 (19 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)Total
Female268
Male251843
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort I (DTG 50 mg OD)Cohort II (DTG 50 mg BID)Total
African American/African Heritage358
White-Arabic/North African Heritage112
White-White/Caucasian/European Heritage231841
08

Study locations

26 sites
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Santa Fe, New Mexico 87505, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H3G 1A4, Canada
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Le Kremlin-Bicêtre Cedex, 94275, France
  • GSK Investigational Site
    Lyon Cedex 03, 69437, France
  • GSK Investigational Site
    Marseille, 13009, France
  • GSK Investigational Site
    Montpellier Cedex 5, 34295, France
  • GSK Investigational Site
    Nice, 06202, France
  • GSK Investigational Site
    Paris Cedex 13, 75651, France
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28029, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
09

References and documents

Publications

  • Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7. PubMed 23225901 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Nov 2010 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 11 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Aug 3, 2009
Start
Aug 2009
Primary completionActual
Nov 2010
CompletionActual
Jan 2015
Results delay requested
Aug 12, 2010
Results first posted
Oct 21, 2013
Last update
Dec 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00950859
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 3, 2009
Start date
Aug 2009
Primary completion
Nov 2010
Completion
Jan 2015
Results posted
Oct 21, 2013
Last update
Dec 4, 2015

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion